2 recruiting, 2 terminated. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Terminated 2 |
| Phase 2 | 3 | Recruiting 2, Terminated 1 |
Follow Genprex, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients quaratusugene ozeplasmid, atezolizumab - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Recruiting | Genprex, Inc. | 62 | 2024-05-09 | 2026-09-11 |
| Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer quaratusugene ozeplasmid, pembrolizumab, docetaxel - Non Small Cell Lung Cancer | Phase 1 | Terminated | Genprex, Inc. | 5 | 2022-03-30 | 2026-06-03 |
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy - Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Recruiting | Genprex, Inc. | 158 | 2021-09-03 | 2026-09-16 |
| TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone - Lung Cancer | Phase 1 / Phase 2 | Terminated | Genprex, Inc. | 25 | 2014-02-01 | 2022-03-02 |
Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (1)
Calcium Dobesilate (1) · Carboplatin (1) · Cisplatin (1) · Dexamethasone (1) · Diphenhydramine (1) · Docetaxel (1) · Erlotinib Hydrochloride (1) · Platinum Compounds (1) · Ramucirumab (1) · atezolizumab (1) · osimertinib (1) · pembrolizumab (1)
United States (4)
Charles Lu, MD (1) · Daniel Morgensztern, MD (1) · Mark S Berger, MD (1) · Mark S. Berger, MD (1)